Efficacy, safety and tolerability of cotadutide as an add-on therapy in overweight subjects with type 2 diabetes treated with dapagliflozin and metformin

被引：0
|
作者：
Flor, A. [1 ]
Petrone, M. [2 ]
Sanchez, J. [3 ]
Petrohoy, T. [4 ]
Jermutus, L. [2 ]
Hansen, L. [1 ]
Ambery, P. [3 ]
机构：
[1] AstraZeneca, Gaithersburg, MD USA
[2] AstraZeneca, Cambridge, England
[3] AstraZeneca, Gothenburg, Sweden
[4] Pfizer, Collegeville, PA USA
来源：
DIABETOLOGIA | 2021年 / 64卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
476
引用
收藏
页码：247 / 247
页数：1
相关论文
共 50 条
  • [21] Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus
    Masato Odawara
    Izumi Hamada
    Manabu Suzuki
    Diabetes Therapy, 2014, 5 : 169 - 181
  • [22] Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus
    Odawara, Masato
    Hamada, Izumi
    Suzuki, Manabu
    DIABETES THERAPY, 2014, 5 (01) : 169 - 181
  • [23] SOLUTION study: Effect of gemigliptin as add-on therapy to dapagliflozin plus metformin in patients with type 2 diabetes
    Lee, B. W.
    Min, K. W.
    Hong, E. G.
    Ku, B. J.
    Kang, J. G.
    Chon, S.
    Kim, J. H.
    Park, M. K.
    Lee, W. Y.
    Kim, S. Y.
    Song, K. H.
    Yoo, S. J.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [24] Long-term efficacy and safety of add-on dapagliflozin vs add-on glipizide in patients with type 2 diabetes mellitus inadequately controlled with metformin: 2-year results
    Del Prato, S.
    Nauck, M. A.
    Rohwedder, K.
    Theuerkauf, A.
    Langkilde, A. M.
    Parikh, S.
    DIABETOLOGIA, 2011, 54 : S348 - S348
  • [25] Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis
    Yang, Ting
    Lu, Min
    Ma, Lingyue
    Zhou, Ying
    Cui, Yimin
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 71 (11) : 1325 - 1332
  • [26] Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis
    Ting Yang
    Min Lu
    Lingyue Ma
    Ying Zhou
    Yimin Cui
    European Journal of Clinical Pharmacology, 2015, 71 : 1325 - 1332
  • [27] Efficacy and safety of dapagliflozin add-on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study
    Jeong, In-Kyung
    Choi, Kyung Mook
    Han, Kyung Ah
    Kim, Kyoung-Ah
    Kim, In Joo
    Han, Seung Jin
    Lee, Won Young
    Yoo, Soon Jib
    DIABETES OBESITY & METABOLISM, 2024, 26 (11): : 5065 - 5077
  • [28] COST-EFFECTIVENESS OF DAPAGLIFLOZIN AS ADD-ON TO METFORMIN FOR THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Tzanetakos, C.
    Tentolouris, N.
    Kourlaba, G.
    Maniadakis, N.
    VALUE IN HEALTH, 2015, 18 (07) : A606 - A607
  • [29] Economic evaluation of dapagliflozin as add-on to metformin in type 2 diabetes in the Israeli healthcare setting
    Moshel, S.
    Vexberg, M. Hirsch
    Shavit, O.
    Toledano, Y.
    DIABETOLOGIA, 2018, 61 : S311 - S311
  • [30] POSTPRANDIAL DYNAMICS OF PLASMA GLUCOSE, INSULIN, AND GLUCAGON IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN ADD-ON TO METFORMIN THERAPY
    Hansen, Lars
    Iqbal, Nayyar
    Ekholm, Ella
    Cook, William
    Hirshberg, Boaz
    ENDOCRINE PRACTICE, 2014, 20 (11) : 1187 - 1197
12345